Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) announced industry recognitions for employee well-being, earning the 2026 Business Group on Health "Best Employers Award: Excellence in Health & Well-being" and additional "Excellence in Global Health & Well-being" recognition. BD also received Cigna Healthcare 2025 Gold Healthy Workforce Designation and the American Heart Association 2026 Gold Well-being Works Better recognition. These awards reflect BD's holistic global benefits, mental and financial well-being programs, and alignment with its 2030+ sustainability workforce goals.
BD (NYSE: BDX) launched the CentroVena One™ Insertion System on April 29, 2026, the first all-in-one central venous catheter insertion device. The system consolidates introducer needle, syringe, guidewire and catheter to simplify workflow, received FDA 510(k) clearance, entered the FDA Safer Technologies Program, and is now commercially available in the U.S.
BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable June 30, 2026, to shareholders of record as of June 9, 2026. The indicated annual dividend rate equals $4.20 per share.
This is a routine cash dividend declaration affecting shareholder cash returns and yield calculations.
BD (NYSE: BDX) will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026 at 11:40 AM ET. The presentation will be webcast live; a replay will be available on BD's investor relations website at investors.bd.com after the event.
BD (NYSE: BDX) was honored by the Healthcare Industry Resilience Collaborative on April 16, 2026 as the only supplier to win HIRC's inaugural Member Choice Awards in Transparency, Resiliency and Partnership. The awards reflect member-selected recognition for real-world supply chain performance, data sharing, and collaborative execution.
BD noted prior HIRC recognitions, including the Transparency Badge four years running and the Resiliency Badge in 2025, and highlighted its role on HIRC councils shaping standards and best practices.
BD (NYSE: BDX) will report financial results for its second quarter of fiscal 2026 on Thursday, May 7, 2026.
Management will host an audio webcast at 8:00 a.m. ET to discuss results for the quarter ended March 31, 2026, and to provide an update on operations and strategy. Materials and replay will be available at www.bd.com/investors.
BD (NYSE: BDX) announced that Richard (Rick) Byrd will retire after nearly 25 years with the company, remaining in his role through June 2026. Byrd is executive vice president and president of the Interventional Segment since September 2022 and previously led Medication Delivery Solutions and Preanalytical Systems.
BD said Byrd helped expand leadership in Vascular Access Management, advance the One‑Stick Hospital Stay vision and lead manufacturing scale‑up during the COVID‑19 pandemic. BD intends to name a successor prior to his retirement.
BD (NYSE: BDX) announced new clinical findings (April 9, 2026) showing the PureWick® Urine Collection System helped women with nighttime urinary incontinence report better sleep, greater comfort, and ease of use.
In a four-week randomized trial of 165 women across 13 U.S. sites, ~70% said they would continue using PureWick®; study noted low skin irritation and effective urine capture.
BD (NYSE:BDX) announced CE Marking for the Liverty™ TIPS Stent Graft, an adjustable‑diameter device (6–10 mm) designed to treat portal hypertension complications across the EU. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Meeting on April 12, 2026.
The device offers a broad range of covered TIPS stent lengths, a flexible nitinol frame, dual‑layer ePTFE encapsulation, and a triaxial delivery system. In the U.S. the device remains investigational.
BD (NYSE: BDX) on April 7, 2026 launched the HemoSphere Stream™ Module, a compact device that streams continuous, noninvasive beat-to-beat arterial waveform data to compatible multiparameter bedside monitors.
Used with the VitaWave™ Plus Finger Cuff, it forms the VitaWave™ Plus System, validated against arterial line measurements and designed to broaden continuous blood pressure monitoring across care settings.